Introduction
============

Progesterone is, together with estradiol, one of the ovarian steroid hormones. Progesterone fluctuations are pronounced during the menstrual cycle, but even more extreme variations are noted across pregnancy and postpartum. Increasing evidence suggest that progesterone influences emotion processing in healthy, naturally cycling women ([@B50]; [@B9]). So far, earlier work supports worsened emotion recognition, enhanced emotional memory and increased amygdala reactivity at times of luteal phase progesterone levels ([@B53]; [@B45]). Furthermore, progesterone has been implicated as a causal agent for premenstrual syndrome and premenstrual dysphoric disorder (PMDD) ([@B44]; [@B41]). However, while it may be assumed that some of these effects are mediated via the progesterone receptor, some of the typical progesterone-induced mood symptoms could equally well be mediated by γ-aminobutyric acid (GABA)-active progesterone metabolites, such as allopregnanolone ([@B4]). Of relevance, allopregnanolone serum concentrations temporarily follow that of progesterone during the menstrual cycle, but with an off-set of one to two days ([@B37]). Further, whereas progesterone levels increase by 25-fold during the luteal phase, allopregnanolone levels vary by approximately four-fold ([@B36]).

Animal models point to sedative, anxiolytic, anti-convulsant, and neuroprotective properties of allopregnanolone ([@B26]; [@B30]; [@B7]). In humans, a distinct role of allopregnanolone for female mood disorders has been difficult to delineate, and at present findings point in two directions. First, in pregnant women low levels of allopregnanolone have been associated with depressive symptoms ([@B21], [@B22]), and a proof-of-concept study recently demonstrated that allopregnanolone infusion in the postpartum period was able to rapidly alleviate postpartum depressive symptoms ([@B25]). On the other hand, in terms of the menstrual cycle-induced mental health problems, the allopregnanolone antagonist sepranolone was recently demonstrated to hold promise as treatment of PMDD ([@B6]). These disparities in effect may be explained by differences in underlying pathophysiology, but potentially also by a suggested inverted U-shaped relationship between allopregnanolone and psychological wellbeing ([@B3]). The relationship between allopregnanolone and serotonergic neurotransmission has received little attention in humans, but animal studies have shown that acute administration of fluoxetine increases allopregnanolone levels in the brain of female rats ([@B17]; [@B11]) and diminishes their sensitivity to stress ([@B11]). Clearly, further studies are needed to elucidate the role of allopregnanolone in female mood disorders, and its' relationship with the serotonin system.

Recently, menstrual cycle phase-dependent associations between allopregnanolone and fMRI resting state functional connectivity was demonstrated in healthy women ([@B48]). In the mid-follicular phase, allopregnanolone levels correlated negatively with resting state functional connectivity between the seed region of the default mode network, the posterior cingulate cortex, and the somatosensory association cortex in the sensorimotor network. In the late luteal phase, among other associations, allopregnanolone levels correlated negatively with connectivity between another region of the default mode network, the medial prefrontal cortex (mPFC), and primary and association visual cortices, but positively with connectivity between the mPFC and the entorhinal cortex in the limbic system ([@B48]). Moreover, a one-subject longitudinal study found progesterone-dependent modulation of resting state connectivity between the hippocampus and dorsolateral prefrontal cortex ([@B1]). Thus, the primary brain regions of choice for this study were the midbrain, pallidostriatum and prefrontal cortex, all important representatives of serotonergic neurotransmission, and amygdala, insula, posterior cingulate and hippocampus for their association to emotion processing and allopregnanolone or progesterone-influenced connectivity.

In terms of molecular imaging of markers of serotonergic neurotransmission, no study to our knowledge has investigated serotonin transporter (SERT) binding in relation to allopregnanolone. Thus, the present study sought to investigate cerebral SERT binding in relation to allopregnanolone serum levels in women of childbearing age. Allopregnanolone serum concentration was expected to negatively associate with SERT availability, and also to influence measures of mood.

Materials and Methods {#s1}
=====================

Subjects
--------

Healthy women (age \< 50 years) with regular menstrual cycle (23--35 days), BMI \< 50 kg/m^2^, and no use of hormonal contraception or therapy, who had undergone PET scanning on a high resolution research tomograph (HRRT) and had a serum sample from the day of the PET scan stored in the CIMBI Biobank ([@B27]) were included in the study. With these criteria, serum samples of 92 women who had undergone \[^11^C\]DASB scan were available for the study. Two blood samples could not be analyzed for technical reasons, leaving a study population of 90 healthy women for the \[^11^C\]DASB analyses.

Besides exclusion criteria for neuroimaging, we excluded subjects with clinically relevant medical history, such as neurological or psychiatric disorders, and history of severe head trauma, drug or alcohol abuse, or clinically relevant findings on routine blood chemistry were excluded. All participants had normal findings on brain magnetic resonance imaging (MRI) and displayed no psychopathology according to the revised symptom checklist (SCL-90-R) ([@B10]) and the major depression inventory (MDI). The participants have previously been included as healthy volunteers in studies on GnRH agonist treatment ([@B15]; [@B29]; [@B13]), serotonin transporter binding ([@B14]), gastric bypass surgery ([@B19]), and functional connectivity ([@B5]). All projects were approved by the Copenhagen Region Ethics Committee (KF-01-2006-20, KF-01-124/04, H-1-2010-085, and H-2-2010-108), and the women provided written informed consent for participation.

Allopregnanolone Analyses
-------------------------

Blood samples were collected on the day of the PET scan. The blood samples were centrifuged immediately after the phlebotomy and plasma was stored at -20°C. Allopregnanolone plasma concentrations were determined by Umeå Neurosteroid Research Center, in one batch, as previously described ([@B49]). For measurement of allopregnanolone, we used radioimmunoassay (RIA) after a first step involving extraction with diethyl ether and purification by celite chromatography, the latter to reduce cross-reactivity. The antibody used in the RIA had been raised against 3α-hydroxy-20-oxo-5α-pregnan-11-yl carboxymethyl ether coupled with bovine serum albumin (AgriSera AB, Umeå, Sweden). A RackBeta (Wallace, Finland) scintillation counter was used to count the samples. The allopregnanolone detection limit was 25 pg/ml, with intraassay coefficient of variation for of 6.5% and an interassay coefficient of variation of 8.5%.

SERT Imaging
------------

SERT binding was imaged with \[^11^C\]DASB-PET during a 90- min dynamic acquisition directly following the bolus injection of the tracer. A Siemens ECAT HRRT scanner (Siemens, Munich, Germany), operating in three-dimensional acquisition mode, with an in-plane resolution of 2 mm, was used to obtain the PET scans. The outcome of the \[^11^C\]DASB binding was the ratio between specific binding and non-displaceable binding of the tracer. We used a modified reference tissue model, using cerebellum as a reference region (the vermis part excluded), designed to quantify \[^11^C\]DASB (multilinear reference tissue model/multilinear reference tissue model 2) ([@B23]), and implemented in PMOD (version 2.9; PMOD Technologies, Zurich, Switzerland). Movement correction was performed by AIR ([@B56]). The co-registration of the \[^11^C\]DASB mean image to the high-resolution T1-weighted MR image was done using SPM8 ([@B2]). The exact details on the \[^11^C\] DASB imaging has been presented previously ([@B16]).

Volumes of Interest
-------------------

Volumes of interest for this study were outlined on the participant's MRIs, as described previously ([@B46]). In order to constrain the number of statistical comparisons we pooled a number of regions. This approach was based on the observation of high correlation of SERT binding between cortical and high-binding subcortical regions ([@B12]). Thus, an average SERT binding potential was computed for each participant for the prefrontal cortex (computed by pooling orbito-, superior-, and medial- and inferior-frontal cortex), the pallidostriatum (a combined subcortical region), and the midbrain (including the raphe nuclei). These three VOIs were the primary outcomes of the study. In addition, four regions served as secondary VOIs; amygdala, insula, hippocampus, and posterior cingulate cortex. We chose these VOIs as SERT binding in these regions is relevant in relation to previously described allopregnanolone actions ([@B1]; [@B48]). Time-activity curves from the VOIs and cerebellum (nonspecific binding) were only obtained from gray matter voxels, except in the midbrain, where separation of gray and white matter is difficult.

Mood, and Alertness
-------------------

Emotional functioning and mood symptoms were assessed using the following questionnaires: Profile of Mood States (POMS); Cohen's Perceived Stress Scale (PSS); Symptom Checklist-revised (SCL); and Global Severity Index of SLC score (SCL-GSI). A Simple Reaction Time task was performed to measure general alertness and motor speed, as described in ([@B43]).

5-HTTLPR
--------

The serotonin transporter-linked polymorphic region (5-HTTLPR) ([@B20]; [@B28]) was genotyped in 87 of the participating women, as described in ([@B24]). Genotype frequencies were in Hardy-Weinberg equilibrium; SS = 22.2%, SL = 41.1%, and LL = 33.3%).

Statistics
----------

The association between allopregnanolone serum concentrations and SERT binding was evaluated by multiple linear regression models. Previous findings have indicated that cerebral SERT binding is influenced by season, age (declining with increasing age), and body mass index (BMI) ([@B24]; [@B51]). For these reasons, the weighted least square regression models of SERT binding included age, BMI, and daylight minutes as covariates, all entered as continuous variables. Because allopregnanolone levels were not normally distributed, we also weighted the regression models against the rank order of allopregnanolone. Further all models were carefully checked to ensure that unstandardized residuals were normally distributed. Finally, we validated the weighted least square regression models by use of robust linear regression using an MM estimator.

Path analysis, with bootstrapping to yield confidence intervals for the indirect effect, was performed to evaluate if the effect of allopregnanolone on simple reaction latency was mediated by prefrontal cortex SERT binding. Statistical analyses were performed by SPSS 24.0, SPSS Amos 24.0, and R 3.4.3 using the RobustBase 0.92 package.

Results
=======

As described in Table [1](#T1){ref-type="table"}, women were on average young adults, slightly over-weight and healthy from a psychiatric perspective. According to normative allopregnanolone levels ([@B36]), the majority of women was assessed in the follicular phase, 82/90 (91.1%). The highest SERT binding levels on average were found in the midbrain and pallidostriatum, whereas the lowest levels were noted in the prefrontal cortex and posterior cingulate (Table [1](#T1){ref-type="table"}).

###### 

Demographic data, allopregnanolone levels, and \[^11^C\]DASB binding in the brain.

                                  *n* = 90      
  ------------------------------- ------------- ------------
  Age, years                      27.4 ± 8.2    18--49
  BMI, kg/m^2^                    25.4 ± 6.3    17.0--43.9
  Allopregnanolone, nmol/l        0.61 ± 0.50   0.13--3.70
  Estradiol, pmol/l^a^            203 ± 130     60--810
  Progesterone, nmol/l^a^         0.2 ± 0.13    0.06--0.8
  Daylight, minutes               739 ± 201     426--1052
  SCL global severity index       0.3 ± 0.2     0.01--1.16
  Total Mood Disturbance score    5.7 ± 20.5    -21--86
  **\[^11^C\]DASB BP~ND~**                      
  Prefrontal cortex               0.38 ± 0.09   0.12--0.61
  Midbrain                        2.06 ± 0.29   1.22--2.71
  Pallidostriatum                 1.98 ± 0.35   1.12--3.02
  Total amygdala                  1.78 ± 0.35   0.82--3.04
  Total insula                    0.89 ± 0.14   0.42--1.32
  Total hippocampus               0.71 ± 0.13   0.33--1.09
  Total posterior cingulate       0.49 ± 0.10   0.16--0.69
  Injected dose, MBq              571 ± 56      360--642
  Injected mass per kilo, μg/kg   0.03 ± 0.04   0.00--0.24
  Specific activity, GBq/mmol     177 ± 136     10.0--675

a

Estradiol and progesterone serum concentrations only available in 72 women. SCL-GSI, Global Severity Index of the Symptom Checklist-revised score.

Serum allopregnanolone levels were negatively associated with SERT binding in the prefrontal cortex, pallidostriatum, insula, posterior cingulate, and hippocampus (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). Overall, the models, which also included age, BMI and daylight minutes, explained 6--23% of the variance in SERT binding levels across regions of interest, with the highest explanatory value in the midbrain, and the lowest in the prefrontal cortex (prefrontal cortex: (slope = -0.038, *SD* = 0.017, β = -0.248, *p* = 0.024) (Table [2](#T2){ref-type="table"}). However, the only allopregnanolone association that survived robust regression was the one with SERT binding in the prefrontal cortex (slope = -0.011, *SD* = 0.003, β = -0.196, *p* \< 0.001), whereas the robust regressions between allopregnanolone and SERT binding in the pallidostriatum and hippocampus were in borderline significance (pallidostriatum; slope = -0.162, *SD* = 0.083, β = -0.236, *p* = 0.054, hippocampus; slope = -0.049, *SD* = 0.027, β = -0.187, *p* = 0.071). Further, the negative association between allopregnanolone and prefrontal cortex SERT binding remained when also adjusted for estradiol levels (slope = -0.092, *SD* = 0.029, β = -0.359, *p* = 0.002, *n* = 70). Considering 5-HTTLPR genotype, as a proxy of SERT functionality, did not influence any of the above mentioned findings (tested both as first order effects and interactions).

###### 

Multiple linear regression analyses on allopregnanolone influence on \[^11^C\]DASB binding.

                              Slope                             Adjusted
  --------------------------- -------- ------- -------- ------- ----------
  Prefrontal cortex           -0.038   0.017   -0.248   0.024   0.06
  Midbrain                    -0.070   0.048   -0.149   0.147   0.16
  Pallidostriatum             -0.172   0.006   -0.302   0.005   0.10
  Total amygdala              -0.116   0.062   -0.146   0.067   0.06
  Total insula                -0.072   0.025   -0.300   0.005   0.11
  Total hippocampus           -0.062   0.022   -0.293   0.006   0.13
  Total posterior cingulate   -0.044   0.016   -0.264   0.008   0.23
                                                                

Models adjusted for age, BMI, daylight minutes on the scanning day, and weighted against rank order of allopregnanolone levels.

![Linear association between prefrontal cortex SERT binding and serum allopregnanolone level in women of fertile age, slope = --0.038, *SD* = 0.017, β = --0.248, *p* = 0.024.](fpsyg-09-02767-g001){#F1}

Allopregnanolone levels were negatively correlated with mean reaction latency and percent correct trials in the Simple Reaction Test, Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Women who reacted slower displayed higher allopregnanolone levels, and similarly, made more errors (Table [3](#T3){ref-type="table"}). The path analysis revealed that allopregnanolone exerted a significant direct effect on frontal cortex SERT binding (standardized estimate -0.321, *p* = 0.034) and a borderline significant effect on reaction latency (standardized estimate -0.179, *p* = 0.061). However, the indirect effect of allopregnanolone on reaction latency, mediated by prefrontal cortex SERT binding in the path model, was insignificant (standardized estimate -0.066, *p* = 0.061). Allopregnanolone serum concentrations did not influence any of the emotion- or stress-related measures (Table [3](#T3){ref-type="table"}).

###### 

Correlations between allopregnanolone and mood proxies.

                                            *n*      Spearman Rho      *p*
  ----------------------------------------- -------- ----------------- -----------
  POMS Total Mood Disturbance (TMD) score   75       0.176             0.132
  SCL-GSI                                   90       0.136             0.202
  Cohen PSS                                 89       0.015             0.891
  **SRT total mean reaction latency**       **64**   -0.267            **0.033**
  **SRT percent correct trials**            **64**   \-**0**.**309**   **0.013**

POMS, Profile of Mood States; PSS, Perceived Stress Scale; SCL, Symptom Checklist-revised; SCL-GSI, Global Severity Index of SLC score; SRT, Simple Reaction Test; TMD, Total Mood Disturbance. SRT, Simple Reaction Task.

![Linear association between mean reaction latency in the simple reaction test and allopregnanolone levels in women of fertile age, Spearman's rho = --0.267, *p* = 0.033.](fpsyg-09-02767-g002){#F2}

Discussion
==========

Mapping of the allopregnanolone-serotonin transporter relationship in women of fertile age demonstrated a negative correlation between peripheral levels of this neuroactive steroid and prefrontal cortex availability of the protein responsible for serotonin re-uptake from the synaptic cleft. The major limitations of this study was that measurements were mostly performed in the follicular phase, and that the study only included healthy women.

Allopregnanolone, produced both by the ovaries and in the brain, acts not only as a transcription regulator but also as a GABA agonist by binding to its site on the GABA receptor A (GABA~A~). Allopregnanolone binding to the GABA~A~ receptor leads to enhanced chloride ion flow and decreased GABA unbinding, which is reflected by increased frequency of inhibitory postsynaptic current and desensitization of the receptor ([@B54]). With GABA being the major inhibitory neurotransmitter in the brain, present in one third of all synapses, the effects of allopregnanolone are expected to be widely spread, albeit with some differences, depending on the localization and subunits of the GABA~A~ receptor ([@B54]). As the women in this study were assessed at a time-point when progesterone and allopregnanolone levels are low, the present findings may reflect interactions between SERT and GABA-mediated tonic conductance at the extra-synaptic level, via α~4~β~2~δ GABA receptors ([@B54]). Presence of GABA~A~ receptors outside the synaptic cleft has been shown in the hippocampal formation and cortex ([@B54]), brain regions expressing SERT. Additionally, phasic modulation of neuronal excitability by GABA can be also influenced by synaptic GABA~A~ receptors found ubiquitously in the brain ([@B54]). Clearly, longitudinal investigations will be needed to understand the relationship between serotonergic neurotransmission and fluctuations of allopregnanolone and mood across the menstrual cycle.

The present findings highlight a relationship between allopregnanolone and SERT, particularly in the prefrontal cortex. In this key region for higher cognitive functions and top-down regulation of emotions, GABA as well as serotonergic projections are widespread ([@B31]). Some evidence on GABA-serotonin reciprocal modulation may be derived from animal studies ([@B47]; [@B57]), but human data is scarce. In terms of molecular imaging of markers of serotonergic neurotransmission in relation to progesterone, 5-HT~1A~ receptor binding was negatively correlated with progesterone at the whole brain level in postmenopausal women ([@B42]), whereas combined estrogen-progesterone treatment in postmenopausal women was associated with widespread increased cortical 5-HT~2A~ receptor binding ([@B32]; [@B33]). However, binding of these two receptors did not correlate with progesterone in another study of pre- and post-menopausal women ([@B34]). To our knowledge, this is the first study investigating SERT binding in relation to the progesterone metabolite allopregnanolone in women of fertile age.

Higher SERT in the presence of low allopregnanolone levels, and independently of estradiol levels, may explain psychological well-being during the follicular phase of the menstrual cycle. In fact, no association of allopregnanolone with mood and stress was found in this group of healthy women, likely because of the healthy state and the limited variation in these measures during the follicular phase. Previously, lower SERT binding has been associated with depression ([@B38]; [@B35]). Dysregulation of both allopregnanolone and serotonin have been implicated in anxiety, irritability aggressiveness, as well as cognitive impairment ([@B40]); however, knowledge of their interaction at the molecular level is scarce. While enhancing effects of SSRIs on peripheral allopregnanolone levels have been demonstrated ([@B52]; [@B18]; [@B39]), effects in the other direction remain to be studied. Additionally, neurotrophic-like functions have been demonstrated for both allopregnanolone and serotonin, though more limited to developmental stages for serotonin ([@B55]); and brain-derived neurotrophic factor (BDNF) may be one link. The less functional variant of a polymorphism in the brain derived-neurotrophic factor gene (*BDNF*), but not the short allele of 5-HTTLPR, has for example been associated with decreased fronto-cingulate activity in response to emotional stimuli in PMDD patients in the luteal phase ([@B8]). In line, no 5-HTTLPR genotype effect was observed in the present study.

We found a negative association between allopregnanolone and general alertness, as measured by the Simple Reaction Test. This finding was expected, given the agonistic effects of allopregnanolone on the GABA~A~ receptor ([@B54]). In line with a direct effect on the GABA~A~ receptor, we found no evidence that slower reaction times was mediated by lower SERT binding.

Conclusion
==========

To conclude, considering strengths and limitations of the study, the present findings add knowledge to our understanding of allopregnanolone-SERT neurochemistry in brain regions regulating cognition and emotion processing of potential relevance for sex-specific psychiatric disorders. Further studies with samples from the luteal phase, and also including women with diagnosed PMDD, are needed before a full interpretation of the allopregnanolone-SERT relationship can be made.
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